Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study

Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study

Abstract To evaluate the efficacy and safety of KN026, a novel bispecific HER2 (ECD2 and ECD4) antibody, plus KN046, a PD-L1, and CTLA4 bispecific antibody, in patients with advanced HER2-positive solid tumors. We conducted two sequentially designed phase Ib and II studies with similar target popula...

Full description

Saved in:
Bibliographic Details
Main Authors: Dan Liu, Jifang Gong, Jian Li, Changsong Qi, Zuoxing Niu, Bo Liu, Zhi Peng, Suxia Luo, Xicheng Wang, Yakun Wang, Rusen Zhao, Lilin Chen, Ting Deng, Zhen Li, Lei Chen, Meimei Fang, Hongwei Yang, Linzhi Lu, Yanming Zhang, Fengling Kang, Ting Xu, Xiaotian Zhang, Lin Shen
Format: Article
Language:English
Published: Nature Publishing Group 2025-03-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-025-02195-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41392-025-02195-x

Similar Items